United Therapeutics nabs competing PAH drug with $216M SteadyMed buy
Brief:
United Therapeutics announced Monday morning that it will acquire competitor SteadyMed for $4.46 per share in cash upfront and another $2.63 per share in c...
From Depression to Deep-Learning: Leveraging iPSC and AI Platforms for Evidence-Based Depression Treatment
Continue readingAdvertisement
Advertisement
Advertisement
Advertisement
IBI – International Biopharmaceutical Industry was established to fill in the void for effective marketing and communication between all stakeholders in the Life sciences sector globally.